Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369351 | 0.91 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL3367110 | 0.85 | DPP4 (0.77) | DPP4CYP3A4 | |
| SCHEMBL3369228 | 0.85 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL3368862 | 0.85 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL3368535 | 0.85 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL3369473 | 0.84 | DPP4 (1.00) | DPP4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL3368248 | 0.84 | DPP4 (0.76) | DPP4CYP3A4 | |
| SCHEMBL3369330 | 0.83 | DPP4 (0.84) | DPP4CYP3A4 | |
| SCHEMBL3369028 | 0.82 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL3367635 | 0.81 | DPP4 (1.00) | DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476435-B1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | claimed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | claimed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | claimed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | claimed |
| EP-1476435-B1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1476435-B1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7022718-B2 | Pyridine and pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | BOEHRINGER MARKUS (CH) | 2005-06-30 | — | — | US | disclosed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | DPP4 1/4885CYP3A4 76/4885ALDH1A1 152/4885 |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, PDXK | DPP4 1/4885CYP3A4 70/4885ALDH1A1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.